-Shane T Grey Researcher Activity Profile

Research Author Detailed Information 

Shane T Grey Publication Rate By Year

Shane T Grey has published 2 paper(s) in 1999, 1 paper(s) in 2002, 2 paper(s) in 2003, 1 paper(s) in 2004, 2 paper(s) in 2005, 3 paper(s) in 2006, 2 paper(s) in 2008, for a total of 13 research publications in total.

Shane T St Grey Author Information

LAST NAME: grey

FIRST NAME: Shane T

INITIALS: st

AFFILIATION:

Papers

Shane T Grey's Publication Record

1. Invasion of the killer B's in type 1 diabetes. Year Published: 2006
Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst NSW 2010, Australia.
2. A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. Year Published: 2002
Department of Surgery and Medicine, Immunobiology Research Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA.
3. Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function. Year Published: 2003
Immunobiology Research Center, Department of Surgery and Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. sgrey@caregroup.harvard.edu
4. A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. Year Published: 2003
Immunobiology Research Center, Department of Surgery and Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 02215, USA.
5. A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation. Year Published: 2004
Department of Surgery and Medicine, 99 Brookline Ave, Boston MA 02215, USA.
6. A novel function for A20 in smooth muscle cells: inhibition of activation and proliferation. Year Published: 1999
Immunobiology Research Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
7. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets. Year Published: 1999
Immunobiology Research Center, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. sgrey@caregroup.harvard.edu
8. Functional dichotomy of A20 in apoptotic and necrotic cell death. Year Published: 2005
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. pstorz@bidmc.harvard.edu
9. Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells. Year Published: 2005
Division of Vascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
10. A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia. Year Published: 2006
The Immunobiology Research Center, Harvard Medical School, Boston Massachusetts, USA.
11. Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection. Year Published: 2006
Arthritis and Inflammation Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
12. Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Year Published: 2008
Senior Research Fellow, Gene Therapy and Autoimmunity Group, Arthritis and Inflammation Program, Garvan Institute of Medical Research, 384 Victoria St., Darlinghurst, N5W 2010, Australia.
13. Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Year Published: 2008
Senior Research Fellow, Gene Therapy and Autoimmunity Group, Arthritis and Inflammation Program, Garvan Institute of Medical Research, 384 Victoria St., Darlinghurst, N5W 2010, Australia.